The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 6, 2026 | Frazier Life Sciences XI, L.P. | 10% Owner | Conversion(C) | 1.7M | — | — |
| Aug 6, 2026 | Frazier Life Sciences XI, L.P. | 10% Owner | Conversion(C) | 1.6M | — | — |
| Aug 6, 2026 | Frazier Life Sciences XI, L.P. | 10% Owner | Conversion(C) | 1.2M | — | — |
| Aug 6, 2026 | Frazier Life Sciences XI, L.P. | 10% Owner | Conversion(C) | 961K | — | — |
| Aug 6, 2026 | Frazier Life Sciences XI, L.P. | 10% Owner | Buy(P) | 588K | $17.00 | $10.0M |
| Aug 6, 2026 | Frazier Life Sciences XI, L.P. | 10% Owner | Conversion(C) | 16.3M | — | $0 |
| Aug 6, 2026 | Frazier Life Sciences XI, L.P. | 10% Owner | Conversion(C) | 14.8M | — | $0 |
| Aug 6, 2026 | Frazier Life Sciences XI, L.P. | 10% Owner | Conversion(C) | 11.1M | — | $0 |
| Aug 6, 2026 | Frazier Life Sciences XI, L.P. | 10% Owner | Conversion(C) | 8.9M | — | $0 |
| Aug 6, 2026 | Sanofi | 10% Owner | Conversion(C) | 783K | — | — |
| Aug 6, 2026 | Sanofi | 10% Owner | Buy(P) | 300K | $17.00 | $5.1M |
| Aug 6, 2026 | Sanofi | 10% Owner | Conversion(C) | 783K | — | — |
| Aug 6, 2026 | Redmile Group, LLC | 10% Owner | Conversion(C) | 783K | — | — |
| Aug 6, 2026 | Redmile Group, LLC | 10% Owner | Buy(P) | 200K | $17.00 | $3.4M |
| Aug 6, 2026 | Redmile Group, LLC | 10% Owner | Buy(P) | 400K | $17.00 | $6.8M |
| Aug 6, 2026 | Redmile Group, LLC | 10% Owner | Conversion(C) | 783K | — | — |
| Aug 6, 2026 | venBio Global Strategic Fund IV, L.P. | 10% Owner | Conversion(C) | 2.3M | — | — |
| Aug 6, 2026 | venBio Global Strategic Fund IV, L.P. | 10% Owner | Conversion(C) | 822K | — | — |
| Aug 6, 2026 | venBio Global Strategic Fund IV, L.P. | 10% Owner | Conversion(C) | 665K | — | — |
| Aug 6, 2026 | venBio Global Strategic Fund IV, L.P. | 10% Owner | Buy(P) | 382K | $17.00 | $6.5M |
| Aug 6, 2026 | venBio Global Strategic Fund IV, L.P. | 10% Owner | Conversion(C) | 21.5M | — | $0 |
| Aug 6, 2026 | venBio Global Strategic Fund IV, L.P. | 10% Owner | Conversion(C) | 7.6M | — | $0 |
| Aug 6, 2026 | venBio Global Strategic Fund IV, L.P. | 10% Owner | Conversion(C) | 6.2M | — | $0 |
| Aug 6, 2026 | Deep Track Biotechnology Master Fund, Ltd. | 10% Owner | Conversion(C) | 2.0M | — | — |
| Aug 6, 2026 | Deep Track Biotechnology Master Fund, Ltd. | 10% Owner | Conversion(C) | 18.2M | — | $0 |
| Aug 6, 2026 | Walsh Colin | Director | Conversion(C) | 2.0M | — | $0 |
| Aug 6, 2026 | Walsh Colin | Director | Conversion(C) | 478K | — | $0 |
| Aug 6, 2026 | Walsh Colin | Director | Buy(P) | 500K | $17.00 | $8.5M |
| Aug 6, 2026 | Walsh Colin | Director | Conversion(C) | 18.2M | — | $0 |
| Aug 6, 2026 | Walsh Colin | Director | Conversion(C) | 4.4M | — | $0 |
| Aug 6, 2026 | Goldman Sachs Group Inc | Insider | Conversion(C) | 2.0M | — | $0 |
| Aug 6, 2026 | Goldman Sachs Group Inc | Insider | Conversion(C) | 478K | — | $0 |
| Aug 6, 2026 | Goldman Sachs Group Inc | Insider | Buy(P) | 500K | $17.00 | $8.5M |
| Aug 6, 2026 | Goldman Sachs Group Inc | Insider | Conversion(C) | 18.2M | — | $0 |
| Aug 6, 2026 | Goldman Sachs Group Inc | Insider | Conversion(C) | 4.4M | — | $0 |
| Aug 5, 2026 | Walsh Colin | Director | Buy(P) | 85K | $21.00 | $1.8M |
| Aug 5, 2026 | Walsh Colin | Director | Sell(S) | 988 | $22.03 | $22K |
| Aug 5, 2026 | Walsh Colin | Director | Sell(S) | 447 | $21.87 | $10K |
| Aug 5, 2026 | Walsh Colin | Director | Sell(S) | 1K | $22.03 | $29K |
| Aug 5, 2026 | Walsh Colin | Director | Sell(S) | 200 | $22.05 | $4K |
| Aug 5, 2026 | Walsh Colin | Director | Sell(S) | 2K | $22.06 | $34K |
| Aug 5, 2026 | Walsh Colin | Director | Sell(S) | 3K | $22.02 | $75K |
| Aug 5, 2026 | Walsh Colin | Director | Sell(S) | 200 | $22.10 | $4K |
| Aug 5, 2026 | Walsh Colin | Director | Sell(S) | 480 | $21.55 | $10K |
| Aug 5, 2026 | Walsh Colin | Director | Sell(S) | 100 | $22.11 | $2K |
| Aug 5, 2026 | Walsh Colin | Director | Sell(S) | 753 | $21.97 | $17K |
| Aug 5, 2026 | Walsh Colin | Director | Sell(S) | 672 | $22.02 | $15K |
| Aug 5, 2026 | Walsh Colin | Director | Sell(S) | 7K | $22.03 | $154K |
| Aug 5, 2026 | Walsh Colin | Director | Sell(S) | 400 | $22.02 | $9K |
| Aug 5, 2026 | Walsh Colin | Director | Sell(S) | 1K | $21.84 | $26K |
| Aug 5, 2026 | Walsh Colin | Director | Sell(S) | 1K | $22.05 | $23K |
| Aug 5, 2026 | Walsh Colin | Director | Sell(S) | 300 | $20.84 | $6K |
| Aug 5, 2026 | Walsh Colin | Director | Sell(S) | 443 | $21.78 | $10K |
| Aug 5, 2026 | Walsh Colin | Director | Sell(S) | 200 | $22.05 | $4K |
| Aug 5, 2026 | Walsh Colin | Director | Sell(S) | 700 | $22.07 | $15K |
| Aug 5, 2026 | Walsh Colin | Director | Sell(S) | 1K | $22.19 | $26K |
| Aug 5, 2026 | Walsh Colin | Director | Sell(S) | 100 | $21.99 | $2K |
| Aug 5, 2026 | Walsh Colin | Director | Sell(S) | 7K | $21.61 | $146K |
| Aug 5, 2026 | Walsh Colin | Director | Sell(S) | 76K | $21.04 | $1.6M |
| Aug 5, 2026 | Goldman Sachs Group Inc | Insider | Buy(P) | 85K | $21.00 | $1.8M |
| Aug 5, 2026 | Goldman Sachs Group Inc | Insider | Sell(S) | 988 | $22.03 | $22K |
| Aug 5, 2026 | Goldman Sachs Group Inc | Insider | Sell(S) | 447 | $21.87 | $10K |
| Aug 5, 2026 | Goldman Sachs Group Inc | Insider | Sell(S) | 1K | $22.03 | $29K |
| Aug 5, 2026 | Goldman Sachs Group Inc | Insider | Sell(S) | 200 | $22.05 | $4K |
| Aug 5, 2026 | Goldman Sachs Group Inc | Insider | Sell(S) | 2K | $22.06 | $34K |
| Aug 5, 2026 | Goldman Sachs Group Inc | Insider | Sell(S) | 3K | $22.02 | $75K |
| Aug 5, 2026 | Goldman Sachs Group Inc | Insider | Sell(S) | 200 | $22.10 | $4K |
| Aug 5, 2026 | Goldman Sachs Group Inc | Insider | Sell(S) | 480 | $21.55 | $10K |
| Aug 5, 2026 | Goldman Sachs Group Inc | Insider | Sell(S) | 100 | $22.11 | $2K |
| Aug 5, 2026 | Goldman Sachs Group Inc | Insider | Sell(S) | 753 | $21.97 | $17K |
| Aug 5, 2026 | Goldman Sachs Group Inc | Insider | Sell(S) | 672 | $22.02 | $15K |
| Aug 5, 2026 | Goldman Sachs Group Inc | Insider | Sell(S) | 7K | $22.03 | $154K |
| Aug 5, 2026 | Goldman Sachs Group Inc | Insider | Sell(S) | 400 | $22.02 | $9K |
| Aug 5, 2026 | Goldman Sachs Group Inc | Insider | Sell(S) | 1K | $21.84 | $26K |
| Aug 5, 2026 | Goldman Sachs Group Inc | Insider | Sell(S) | 1K | $22.05 | $23K |
| Aug 5, 2026 | Goldman Sachs Group Inc | Insider | Sell(S) | 300 | $20.84 | $6K |
| Aug 5, 2026 | Goldman Sachs Group Inc | Insider | Sell(S) | 443 | $21.78 | $10K |
| Aug 5, 2026 | Goldman Sachs Group Inc | Insider | Sell(S) | 200 | $22.05 | $4K |
| Aug 5, 2026 | Goldman Sachs Group Inc | Insider | Sell(S) | 700 | $22.07 | $15K |
| Aug 5, 2026 | Goldman Sachs Group Inc | Insider | Sell(S) | 1K | $22.19 | $26K |
| Aug 5, 2026 | Goldman Sachs Group Inc | Insider | Sell(S) | 100 | $21.99 | $2K |
| Aug 5, 2026 | Goldman Sachs Group Inc | Insider | Sell(S) | 7K | $21.61 | $146K |
| Aug 5, 2026 | Goldman Sachs Group Inc | Insider | Sell(S) | 76K | $21.04 | $1.6M |
| Aug 4, 2026 | Veiby Petter | Chief Scientific Officer | Grant(A) | 140K | — | $0 |
| Aug 4, 2026 | You Angie | Director | Grant(A) | 27K | — | $0 |
| Aug 4, 2026 | Gold Mitchell | Director | Grant(A) | 27K | — | $0 |
| Aug 4, 2026 | Chen Hubert | Chief Medical Officer | Grant(A) | 140K | — | $0 |
| Aug 4, 2026 | Odrowaz Zaneta | Chief Business Officer | Grant(A) | 140K | — | $0 |
| Aug 4, 2026 | Attovia Therapeutics, Inc. | Chief Financial Officer | Grant(A) | 140K | — | $0 |
| Aug 4, 2026 | Attovia Therapeutics, Inc. | President and CEO, Director | Grant(A) | 538K | — | $0 |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Coverage: Form 4 filings indexed 2009-03-30 → 2026-08-14. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).
Connected pages for ATTO